{"title":"PD-1 信号限制磷脂磷酸酶 1 的表达并促进瘤内 CD8+ T 细胞铁变态反应","authors":"Yu Ping, Jiqi Shan, Haiming Qin, Feng Li, Jiao Qu, Ru Guo, Dong Han, Wei Jing, Yaqing Liu, Jinyan Liu, Zhangnan Liu, Jieyao Li, Dongli Yue, Feng Wang, Liping Wang, Bin Zhang, Bo Huang, Yi Zhang","doi":"10.1016/j.immuni.2024.08.003","DOIUrl":null,"url":null,"abstract":"<p>The tumor microenvironment (TME) promotes metabolic reprogramming and dysfunction in immune cells. Here, we examined the impact of the TME on phospholipid metabolism in CD8<sup>+</sup> T cells. In lung cancer, phosphatidylcholine (PC) and phosphatidylethanolamine (PE) were lower in intratumoral CD8<sup>+</sup> T cells than in circulating CD8<sup>+</sup> T cells. Intratumoral CD8<sup>+</sup> T cells exhibited decreased expression of phospholipid phosphatase 1 (PLPP1), which catalyzes PE and PC synthesis. T cell-specific deletion of <em>Plpp1</em> impaired antitumor immunity and promoted T cell death by ferroptosis. Unsaturated fatty acids in the TME stimulated ferroptosis of <em>Plpp1</em><sup><em>−/−</em></sup> CD8<sup>+</sup> T cells. Mechanistically, programmed death-1 (PD-1) signaling in CD8<sup>+</sup> T cells induced GATA1 binding to the promoter region <em>Plpp1</em> and thereby suppressed <em>Plpp1</em> expression. PD-1 blockade increased <em>Plpp1</em> expression and restored CD8<sup>+</sup> T cell antitumor function but did not rescue dysfunction of <em>Plpp1</em><sup><em>−/−</em></sup> CD8<sup>+</sup> T cells. Thus, PD-1 signaling regulates phospholipid metabolism in CD8<sup>+</sup> T cells, with therapeutic implications for immunotherapy.</p>","PeriodicalId":13269,"journal":{"name":"Immunity","volume":"146 1","pages":""},"PeriodicalIF":25.5000,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PD-1 signaling limits expression of phospholipid phosphatase 1 and promotes intratumoral CD8+ T cell ferroptosis\",\"authors\":\"Yu Ping, Jiqi Shan, Haiming Qin, Feng Li, Jiao Qu, Ru Guo, Dong Han, Wei Jing, Yaqing Liu, Jinyan Liu, Zhangnan Liu, Jieyao Li, Dongli Yue, Feng Wang, Liping Wang, Bin Zhang, Bo Huang, Yi Zhang\",\"doi\":\"10.1016/j.immuni.2024.08.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The tumor microenvironment (TME) promotes metabolic reprogramming and dysfunction in immune cells. Here, we examined the impact of the TME on phospholipid metabolism in CD8<sup>+</sup> T cells. In lung cancer, phosphatidylcholine (PC) and phosphatidylethanolamine (PE) were lower in intratumoral CD8<sup>+</sup> T cells than in circulating CD8<sup>+</sup> T cells. Intratumoral CD8<sup>+</sup> T cells exhibited decreased expression of phospholipid phosphatase 1 (PLPP1), which catalyzes PE and PC synthesis. T cell-specific deletion of <em>Plpp1</em> impaired antitumor immunity and promoted T cell death by ferroptosis. Unsaturated fatty acids in the TME stimulated ferroptosis of <em>Plpp1</em><sup><em>−/−</em></sup> CD8<sup>+</sup> T cells. Mechanistically, programmed death-1 (PD-1) signaling in CD8<sup>+</sup> T cells induced GATA1 binding to the promoter region <em>Plpp1</em> and thereby suppressed <em>Plpp1</em> expression. PD-1 blockade increased <em>Plpp1</em> expression and restored CD8<sup>+</sup> T cell antitumor function but did not rescue dysfunction of <em>Plpp1</em><sup><em>−/−</em></sup> CD8<sup>+</sup> T cells. Thus, PD-1 signaling regulates phospholipid metabolism in CD8<sup>+</sup> T cells, with therapeutic implications for immunotherapy.</p>\",\"PeriodicalId\":13269,\"journal\":{\"name\":\"Immunity\",\"volume\":\"146 1\",\"pages\":\"\"},\"PeriodicalIF\":25.5000,\"publicationDate\":\"2024-08-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immunity\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.immuni.2024.08.003\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunity","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.immuni.2024.08.003","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
PD-1 signaling limits expression of phospholipid phosphatase 1 and promotes intratumoral CD8+ T cell ferroptosis
The tumor microenvironment (TME) promotes metabolic reprogramming and dysfunction in immune cells. Here, we examined the impact of the TME on phospholipid metabolism in CD8+ T cells. In lung cancer, phosphatidylcholine (PC) and phosphatidylethanolamine (PE) were lower in intratumoral CD8+ T cells than in circulating CD8+ T cells. Intratumoral CD8+ T cells exhibited decreased expression of phospholipid phosphatase 1 (PLPP1), which catalyzes PE and PC synthesis. T cell-specific deletion of Plpp1 impaired antitumor immunity and promoted T cell death by ferroptosis. Unsaturated fatty acids in the TME stimulated ferroptosis of Plpp1−/− CD8+ T cells. Mechanistically, programmed death-1 (PD-1) signaling in CD8+ T cells induced GATA1 binding to the promoter region Plpp1 and thereby suppressed Plpp1 expression. PD-1 blockade increased Plpp1 expression and restored CD8+ T cell antitumor function but did not rescue dysfunction of Plpp1−/− CD8+ T cells. Thus, PD-1 signaling regulates phospholipid metabolism in CD8+ T cells, with therapeutic implications for immunotherapy.
期刊介绍:
Immunity is a publication that focuses on publishing significant advancements in research related to immunology. We encourage the submission of studies that offer groundbreaking immunological discoveries, whether at the molecular, cellular, or whole organism level. Topics of interest encompass a wide range, such as cancer, infectious diseases, neuroimmunology, autoimmune diseases, allergies, mucosal immunity, metabolic diseases, and homeostasis.